<DOC>
	<DOCNO>NCT00911976</DOCNO>
	<brief_summary>The specific aim SOS-Xience V study examine 12-month incidence binary angiographic in-stent restenosis implantation Xience V stent aortocoronary saphenous vein bypass graft lesion .</brief_summary>
	<brief_title>Study Xience V Everolimus-eluting Stent Saphenous Vein Graft Lesions</brief_title>
	<detailed_description>Implantation bare metal coronary stent ( BMS ) currently prefer percutaneous treatment aortocoronary saphenous vein bypass graft ( SVG ) lesion , associate high risk in-stent restenosis . Although drug-eluting stent ( DES ) appear promise , limited conflict data efficacy safety SVGs . Our group recently complete reported result SOS ( Stenting Of Saphenous vein graft ) trial compare paclitaxel-eluting stent similar BMS . There currently data use second generation DES challenging lesion . The SOS-Xience V study examine effect Xience V everolimus-eluting stent SVG lesion . The specific aim SOS-Xience V examine 12-month incidence binary angiographic in-stent restenosis ( defined stenosis &gt; 50 % minimum lumen diameter target segment ) implantation Xience V stent SVG lesion . The Xience V stent implant 40 consecutive patient need stenting SVG lesion . Patients undergo repeat follow-up angiography intravascular ultrasonography 12 month follow clinically 12 month determine : 1. incidence binary angiographic in-stent restenosis , assess 12 month follow-up quantitative coronary angiography ( primary study endpoint ) , 2. intra-stent intimal hyperplasia volume accumulation 12 month , measure intravascular ultrasonography , ( b ) 12-month incidence ischemia-driven target vessel revascularization , stent thrombosis , target vessel failure ( composite cardiac death , myocardial infarction , target vessel revascularization ) ( secondary study endpoint ) , ( c ) percent stent strut coverage optical coherence tomography</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Age &gt; 18 year 2 . Need percutaneous coronary intervention 5099 % de novo SVG lesion 2.5 4.5 mm diameter , â‰¤ 22 mm length , treat implantation single stent 3 . Use embolic protection device SVG intervention 4 . Able willing return angiographic followup 12 month 5 . Agree participate provide inform consent 1 . Use stent Xience V stent 2 . Planned noncardiac surgery within follow 12 month 3 . Presentation STsegment elevation acute myocardial infarction 4 . Any previous percutaneous treatment target lesion ( balloon angioplasty , stent , intravascular brachytherapy etc ) 5 . Any previous percutaneous treatment target vessel ( lesion different target lesion ) within prior 12 month 6 . Hemorrhagic diatheses , refusal receive blood transfusion 7 . Current treatment warfarin 8 . Recent positive pregnancy test , breastfeeding , possibility future pregnancy 9 . Coexisting condition limit life expectancy le 12 month 10 . Patients creatinine 2.5 mg/dL ( unless require hemodialysis , case eligible participate ) 11 . Patients allergic contrast material adequately premedicated 12 . History allergic reaction significant sensitivity everolimus 13 . Documented leave ventricular ejection fraction ( LVEF ) &lt; 25 % recent evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Coronary artery bypass</keyword>
	<keyword>Stents</keyword>
	<keyword>Angioplasty , Transluminal , Percutaneous Coronary</keyword>
	<keyword>Coronary Restenosis</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Saphenous vein graft</keyword>
</DOC>